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Statin therapy has gained interest in the field of hypertension due to
the potential role of different statin agents in blood pressure (BP) lower-
ing [1-3]. The potential mechanisms involved include the downregulation
of the angiotensin II-type 1 receptor, the decrease of vasoconstrictor
endothelin-1 levels, and the increase in the endothelial production of nitric
oxide (NO), an effect that is correlated with the upregulation of endothe-
lial NO synthase expression [4-6]. Furthermore, we have recently report-
ed the effects of statin treatment on endothelial function, oxidative stress
and inflammation in patients with hypertension and normal cholesterol
levels [7]. Yet, despite the beneficial effects shown by statins in hyper-
tensive animal models as well as in small clinical studies, the results from
meta-analyses and large clinical trials have been controversial.
Indeed, the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering
Arm (ASCOT-LLA) [8] demonstrated that the combination of amlodipine-
based therapy and atorvastatin was highly effective in preventing cardio-
vascular (CV) endpoints in hypertensive patients at risk of CV disease, but
the authors did not report any significant effect on BP [8]. However, 
it should be highlighted that the use of anti-hypertensive agents was left
to the discretion of physicians during the trials [8]. Additional information
comes from post-hoc analyses and meta-analyses, suggesting that statins
could lower systolic blood pressure, particularly in patients with high blood
pressure [9]; however, most studies had small sample sizes, were not blind-
ed, and the time of observation was not long enough. 
In addition, several authors have emphasized that hypertension and
hyperlipidaemia seem to be interrelated through common pathophysio-
logical pathways [10] and it has been recently reported [11] that lipopro-
tein size and subclass concentrations, especially small, dense low-densi-
ty lipoproteins (LDL), are associated with incident hypertension and may
provide additional information to traditional CV risk factors [11]. In this
view, it should be highlighted that the most important link between lipid
metabolism and atherosclerosis is based on the formation of foam cells
(the first step of plaque generation) from oxidized, small dense LDL [12].
Indeed, LDL are very heterogeneous particles, which comprise multiple dis-
tinct subclasses that differ in size, density, physico-chemical composition,
metabolic and oxidative behaviour, as well as atherogenicity [13]. Increas-
ing evidence suggests that both the “quality”, and probably especially the
“quantity” of plasma lipids and lipoproteins influence CV risk, as reflect-
ed in the pro-atherogenic alterations that give rise to elevated levels of
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small, dense LDL. The pathophysiology, athero-
genicity and clinical significance of these LDL par-
ticles have already been highlighted in the recent
consensus statement of a European panel of
experts [14, 15]. 
Owczarek et al. in the present issue of Archives
of Medical Science [16] report no beneficial effects
of simvastatin after 4 weeks of therapy on BP and
heart rate after metoprolol injection in animal mod-
els (rats). The authors have already observed sim-
ilar effects in two other studies with a 2-week peri-
od of statin administration [17, 18]. Yet, a reduction
in heart rate and BP has been reported in patients
with hypertension and type-2 diabetes with the
concomitant administration of simvastatin and
metoprolol [19], and other studies evaluated the
effects of such combined therapy on C-reactive pro-
tein levels [20]. We cannot exclude that therapeu-
tic modulation of enhanced inflammation and/or
atherogenic dyslipidaemia may contribute to the
beneficial effect shown by simvastatin on blood
pressure, especially considering that the study by
Owczarek et al. has some important limitations con-
nected to the length of the intervention (only 
4 weeks), the dose and the type of statin, and final-
ly with the selection of hypertension drug: meto-
prolol, an old β1 receptor blocker without a nitric
oxide-potentiating vasodilatory effect [16, 21].
In conclusion, as recently highlighted, there is
more to predicting vascular disease than just estab-
lished risk factors [22]. Patients with hypertension
benefit from statin administration, independently
of their plasma lipid levels, and independently of
the influence on their BP . Inflammation and athero-
genic dyslipidaemia may play a role [23-25]. Future
well-designed clinical trials with carefully selected
endpoints are needed in order to demonstrate
whether statins definitely have an anti-hyperten-
sive effect. Such studies should also investigate the
synergistic effects of hypertension and atherogenic
lipoproteins on CV risk. 
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